Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients

Trial Profile

Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2019

At a glance

  • Drugs LY 3016859 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Jan 2018 Results from two initial early-phase clinical studies(TGAA; NCT01545583 and TGAB; NCT01774981), published in the Clinical Pharmacology in Drug Development Journal.
    • 20 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 20 Jan 2015 Planned End Date changed from 1 Aug 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top